SEC Form 10-K filed by Akari Therapeutics plc
$AKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
8-K - Akari Therapeutics Plc (0001541157) (Filer)
DEF 14A - Akari Therapeutics Plc (0001541157) (Filer)
PRE 14A - Akari Therapeutics Plc (0001541157) (Filer)
Access the "What This Means" segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced it recently participated in a Virtual Investor "What This Means" segment. For the segment, Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed the Company's recently issued India Patent No. 562,919 titled, "Thailanstatin Analogs," covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across var
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a key territory with a rapidly growing incidence rate of cancer cases, projected to increase to 2.08 million by 20401 BOSTON and LONDON, June 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced the Intellectual Property India (IPI) has issued Patent No. 562,919 titled, "Thailanstatin Analogs". The issued patent covers claims for t
Access the video here BOSTON and LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the release of a "Meet the Team" video featuring newly appointed Mark F. Kubik, Head of Business Development – Oncology. The video is now available on the Presentations page under the Investors section of the Company's website (www.akaritx.com). About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform,
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member. We look forward to following her vision and continued leadership as we
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development
Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D - Akari Therapeutics Plc (0001541157) (Subject)